Status:

COMPLETED

Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects

Lead Sponsor:

Sangamo Therapeutics

Conditions:

HIV

HIV Infection

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

This research study is being carried out to study a new way to possibly treat human immunodeficiency virus (HIV). The agent is called SB-728-T which are CD4+ T-cells obtained from an individual that a...

Detailed Description

Laboratory studies have shown that when CD4+ T-cells are modified with Zinc Finger Nucleases SB-728, HIV is prevented from killing the CD4+ T-cells. On the basis of these laboratory results, there is ...

Eligibility Criteria

Inclusion

  • Documented HIV infection
  • CD4+ T-cell count \>500 cell per millimeter cubed (cells/mm3)
  • CD4+ T-cell nadir of \>400 cells/mm3
  • HIV viral load \>1,000 copies per milliliter (mL)

Exclusion

  • Any viral hepatitis
  • Acute HIV infection
  • HIV viral load \>1,000,000 copies/mL
  • Active or recent (prior 6 months) AIDS defining complication
  • Any HIV medications within the past 12 weeks
  • Cancer or malignancy that has not been in remission for at least 5 years with the exception of successfully treated basal cell carcinoma of the skin
  • Current diagnosis of NYHA grade 3 or 4 congestive heart failure or uncontrolled angina or arrhythmias
  • History of bleeding problems
  • Use of chronic steroids in past 30 days
  • Pregnant or breast feeding
  • Active drug or alcohol abuse
  • Serious illness in past 30 days
  • Currently participating in another clinical trail or any prior gene therapy

Key Trial Info

Start Date :

November 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2015

Estimated Enrollment :

21 Patients enrolled

Trial Details

Trial ID

NCT01252641

Start Date

November 1 2010

End Date

May 1 2015

Last Update

September 20 2019

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

UCLA CARE Center

Los Angeles, California, United States, 90035

2

Orange Coast Medical Group

Newport Beach, California, United States, 92663

3

Quest Clinical Research

San Francisco, California, United States, 94115

4

Orlando Immunology Center

Orlando, Florida, United States, 32803